Patiromer: a clinical review

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Hyperkalemia is a serious condition often associated with chronic kidney disease (CKD) and heart failure (HF).
• Renin-angiotensin-aldosterone system inhibitors (RAASis) are crucial for managing these conditions but can cause hyperkalemia.
• Limited therapeutic options exist for managing hyperkalemia, particularly for patients on RAASis.

Purpose of the Study:

• To review the efficacy and safety of patiromer for treating hyperkalemia.
• To compare patiromer's pharmacokinetics with sodium polystyrene sulfonate (SPS).
• To evaluate patiromer's role in enabling continued RAASi therapy in patients with CKD and/or HF.

Main Methods:

• Literature search of PubMed, Google Scholar, fda.gov, and clinicaltrials.gov for studies on patiromer (RLY5016).
• Analysis of clinical trial data, posters, and commentaries focusing on patiromer's use in hyperkalemia management.
• Review of studies involving patients with CKD, T2DM, hypertension, and/or HF receiving RAASis.

Main Results:

• Patiromer effectively reduced serum potassium levels in clinical trials (PEARL-HF, OPAL-HK, AMETHYST-DN).
• It enabled dose titration of spironolactone and allowed patients to remain on RAASi therapy.
• The drug demonstrated sustained potassium reduction for up to one year with a low rate of hypokalemia. Constipation was the most common adverse event.

Conclusions:

• Patiromer is effective in lowering serum potassium and preventing hyperkalemia recurrence.
• It facilitates continued RAASi treatment, which is critical for patients with CKD and HF.
• Patiromer is well-tolerated, with no serious adverse events reported, suggesting it may be a preferred alternative to SPS.